Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Mitomycin
Kyowa Kirin Limited
L01DC; L01DC03
Mitomycin
10 milligram(s)
Powder for solution for injection
Product subject to prescription which may not be renewed (A)
Other cytotoxic antibiotics; mitomycin
Marketed
2003-12-12
1 PATIENT INFORMATION LEAFLET MITOMYCIN-C KYOWA ® 10MG / MITOMYCIN-C KYOWA ® 40MG POWDER FOR SOLUTION FOR INJECTION (Mitomycin-C) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET: 1. What Mitomycin-C Kyowa is and what it is used for 2. What you need to know before you use Mitomycin-C Kyowa 3. How to use Mitomycin-C Kyowa 4. Possible side effects 5. How to store Mitomycin-C Kyowa 6. Contents of the pack and other information 1. WHAT MITOMYCIN-C KYOWA IS AND WHAT IT IS USED FOR Mitomycin-C Kyowa can be used to treat different types of cancers in many different parts of the body as described below: • In bladder cancer Mitomycin-C Kyowa can be administered by injection or, alternatively by instillation directly into the bladder after surgery to reduce the chances of a recurrence of the condition. • In certain types of cancer of the stomach, pancreas, oesophagus, lower bowel, biliary tract and lung Mitomycin-C Kyowa can be used in combination with other drug treatments. • In a type of cancer of the anus, Mitomycin-C Kyowa can be used in combination with other drug treatments or with radiotherapy. • In a certain type of breast cancer, Mitomycin-C Kyowa can be used as a single agent or in combination with other drug treatments. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE MITOMYCIN-C KYOWA DO NOT USE MITOMYCIN-C KYOWA IF YOU: • are allergic (hypersensitive) to mitomycin or any of the other ingredients of Mitomycin-C Kyowa (listed in section 6 Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mitomycin-C Kyowa 10 mg, Powder for Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 10 mg of Mitomycin-C. Each vial also contains 240mg of sodium chloride (equivalent to 4.1 mmol sodium). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for injection (powder for injection) Blue/purple powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mitomycin C must be used under supervision of an Oncologist. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Paediatric population The safety and efficacy of Mitomycin C in children has not yet been established. No data are available. For parenteral use. Intravenously, the dose should be given with great care in order to avoid extravasation. 1. As a single agent in the treatment of superficial bladder cancer. In addition it has been shown that post-operative instillations of Mitomycin-C Kyowa can reduce recurrence rates in newly diagnosed patients with superficial bladder cancer. 2. As a single agent or as part of combination therapy in the treatment of adenocarcinoma of the breast. 3. As part of combination therapy in the treatment of adenocarcinomas of the stomach and oesophagus. 4. Small studies have suggested it may be useful as part of combination therapy in the treatment of adenocarcinomas of the pancreas and biliary tract. 5. As part of combination therapy with other cytotoxic drugs and radiotherapy in the treatment of squamous cell carcinoma of the anus. 6. Small studies have suggested that it may be useful as part of combination therapy in the treatment of non small cell lung cancer. 7. Limited studies suggest it may be useful as part of combination therapy in the treatment of adenocarcinoma of the colon and rectum. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Read the complete document